Pharmacokinetics, tissue residue and plasma protein binding of ofloxacin in goats.
- Author:
Himangshu BARUAH
1
;
Dulal Chandra ROY
;
Rohini Kumar ROY
;
Hirendra Nath KHONIKOR
Author Information
1. Department of Pharmacology and Toxicology, College of Veterinary Science, Assam Agricultural University, Guwahati 781022, Assam, India. h_baruah@rediffmail.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Pharmacokinetics;
Ofloxacin;
dosage;
goats
- MeSH:
Animals;
Anti-Infective Agents/*pharmacokinetics;
Blood Proteins/*metabolism;
Chromatography, High Pressure Liquid/veterinary;
Goats/*metabolism;
Male;
Ofloxacin/*pharmacokinetics;
Protein Binding;
Tissue Distribution
- From:Journal of Veterinary Science
2004;5(2):97-101
- CountryRepublic of Korea
- Language:English
-
Abstract:
Ofloxacin was administered to six male goats intravenously (5 mg/kg) to determine its kinetic behavior, tissue residue, in vitro plasma protein binding and to compute a rational dosage regimen. The concentration of ofloxacin in plasma and tissue samples collected at prescheduled time were estimated by using HPLC. The pharmacokinetic parameters were determined by non-compartmental model and plasma protein binding was estimated by equilibrium dialysis technique. The therapeutic concentration (> or = 0.5 microgram/ml) was maintained up to 36 h and the initial concentration at 2.5min (14.76 +/- 0.47 microgram/ml) declined to 0.05 +/- 0.03 microgram/ml at 96 h with a secondary peak (0.64 +/- 0.15 microgram/ml) at 24 h. The mean AUC, AUMC, t1/2, MRT, Cl and Vd were calculated to be 58.94 +/- 19.43 microgram h/ml, 1539.57 +/- 724.69 microgram h2/ml, 15.58 +/- 1.87 h, 22.46 +/- 2.71 h, 135.60 +/- 31.12 ml/h/kg and 2.85 +/- 0.74 L/kg respectively. Significantly high concentration of drug was detected in different tissues after 24 h of intravenous dosing of 5mg/kg, at 24 h interval for 5 days. The in vitro plasma protein binding of ofloxacin was found to be 15.28 +/- 0.94%. Based on these kinetic parameters, a loading dose of 5mg/kg followed by the maintenance dose of 3mg/kg at 24 h dosing interval by intravenous route is recommended.
